|Evotec AG -- USA Stock|| |
USD 20.35 0.00 0.00%
CFO and Member of Management Board
Mr. Colin Bond is Chief Financial Officer and Member of the Management Board at Evotec AG since August 1 2010. He has almost 25 years of experience in finance positions most recently as Chief Financial Officer of Novelis Europe based in Switzerland. During his early career he worked as pharmacist auditor and management consultant for Procter Gamble Arthur Andersen and PricewaterhouseCoopers respectively. He moved into industry with Great Lakes Chemicals and then became Chief Finance Officer of Jet Aviation Group before becoming CFO EMEA for Ecolab
Age: 54 CFO Since 2010 MBA
49 4056 0810 http://www.evotec.com
Bond is a qualified chartered accountant and pharmacist. He is a fellow of the Institute of Chartered Accountants in England and Wales and is a Member of the Royal Pharmaceutical Society of Great Britain. In addition, he received his MBA degree from London Business School. He is an Associate Lecturer at the Hamburg School of Business Administration.
The company has return on total asset (ROA)
of 4.56 %
which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 11.13 %
meaning that it generated $11.13 on every $100 dollars invested by stockholders.
The company has accumulated 213.24 M in total debt with debt to equity ratio (D/E) of 53.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.68 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Evotec AG offer drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Hamburg, and employs 1,000 people.